Patient flow. The flow of HLA check, donor availability, and actual application of allo-HCT in CR1 are shown. Among the total of 2029 patients with AML in CR1, 494 received allo-HCT in CR1 and were included in the HCT group. Among the remaining 1535 patients, 118 patients who died or relapsed within 3 months were excluded to take into account patients who were unable to receive allo-HCT in CR1 even though they had made a decision to receive HCT in CR1. Consequently, 1417 patients were included in the CTx group. Among them, 478 received allo-HCT after first relapse. The donor group included the 431 patients who had a suitable related donor. The no-donor group included the 645 patients who did not find a related donor and 953 for whom HLA was not typed in CR1. CR1 indicates first complete remission; and HCT, hematopoietic cell transplantation.